Haleon Plc Stock Today
| HLN Stock | USD 10.33 0.01 0.1% |
Performance27 of 100
| Odds Of DistressLess than 9
|
Haleon Plc is selling at 10.33 as of the 9th of September 2024; that is 0.1 percent increase since the beginning of the trading day. The stock's open price was 10.32. Haleon Plc has less than a 9 % chance of experiencing financial distress in the next few years and had a strong performance during the last 90 days. Note, on July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Haleon plc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of July 2022 | Category Healthcare | Classification Health Care |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. The company has 4.56 B outstanding shares of which 14.03 M shares are currently shorted by investors with about 3.76 days to cover. More on Haleon plc
Moving together with Haleon Stock
| 0.81 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
| 0.83 | DMAC | DiaMedica Therapeutics | PairCorr |
Moving against Haleon Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Haleon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Pacific | Keith Choy | ||||
| Thematic Idea | Consumer Goods (View all Themes) | ||||
| Old Name | HOME LN SRV SOL | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Consumer Goods, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsHaleon Plc can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Haleon Plc's financial leverage. It provides some insight into what part of Haleon Plc's total assets is financed by creditors.
| |||||
Haleon plc (HLN) is traded on New York Stock Exchange in USA. It is located in The Heights, Weybridge, United Kingdom, KT13 0NY and employs 25,408 people. Haleon Plc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 47.06 B. Haleon plc runs under Biotechnology sector within Health Care industry. The entity has 4.56 B outstanding shares of which 14.03 M shares are currently shorted by investors with about 3.76 days to cover.
Haleon plc has about 684 M in cash with 1.72 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Haleon Plc Probability Of Bankruptcy
Ownership AllocationHaleon plc has a total of 4.56 Billion outstanding shares. Haleon Plc retains 4.34 (percent) of its outstanding shares held by insiders and 11.49 (percent) owned by outside corporations. Please note that on July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Haleon plc's common stock.
Check Haleon Ownership Details
Haleon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wellington Management Company Llp | 2024-06-30 | 6.1 M | |
| Nuveen Asset Management, Llc | 2024-06-30 | 5.7 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 5.5 M | |
| Bank Of America Corp | 2024-06-30 | 5.1 M | |
| Bain Capital Public Equity Management Ii, Llc | 2024-06-30 | 5 M | |
| Northern Trust Corp | 2024-06-30 | 4.5 M | |
| Raymond James & Associates | 2024-06-30 | 4 M | |
| Wells Fargo & Co | 2024-06-30 | 3.7 M | |
| Van Eck Associates Corporation | 2024-06-30 | 3.3 M | |
| Dodge & Cox | 2024-06-30 | 180.2 M | |
| Fmr Inc | 2024-06-30 | 99.2 M |
Haleon Plc Historical Income Statement
Haleon Stock Against Markets
Haleon Plc Corporate Management
| Tamara Rogers | Chief Officer | Profile | |
| Brian McNamara | CEO Director | Profile | |
| Bjarne Tellmann | General Counsel | Profile | |
| Bart Derde | Head Chain | Profile | |
| Franck Riot | Chief Officer | Profile |
Additional Information and Resources on Investing in Haleon Stock
When determining whether Haleon plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Haleon Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Haleon Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Haleon Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haleon plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Haleon Stock, please use our How to Invest in Haleon Plc guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haleon Plc. If investors know Haleon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haleon Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.032 | Dividend Share 0.062 | Earnings Share 0.31 | Revenue Per Share 2.446 | Quarterly Revenue Growth 0.008 |
The market value of Haleon plc is measured differently than its book value, which is the value of Haleon that is recorded on the company's balance sheet. Investors also form their own opinion of Haleon Plc's value that differs from its market value or its book value, called intrinsic value, which is Haleon Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haleon Plc's market value can be influenced by many factors that don't directly affect Haleon Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haleon Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Haleon Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haleon Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.